Search Results - "Buxo, E."

Home management of acute medical complications in cancer patients: a prospective pilot study by Font, C., Fernández-Avilés, F., Calderon, C., García-Fernández, T., Arab, N., Pineda, E., Buxó, E., Ayora, P., Carreño, M., Pereira, V., Viladot, M., Moreno, C., Gallego, C., Hernando, A., Creus, N., Barrera, C., Alcaraz, R., Sanchez, J., Prat, A., Tuca, A.

“…Background The development of reliable alternatives to conventional hospitalization in patients with cancer would have great clinical and economical value. The…”
Get full text

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab by Custodio, A, Carmona-Bayonas, A, Jiménez-Fonseca, P, Sánchez, M L, Viudez, A, Hernández, R, Cano, J M, Echavarria, I, Pericay, C, Mangas, M, Visa, L, Buxo, E, García, T, Rodríguez Palomo, A, Álvarez Manceñido, F, Lacalle, A, Macias, I, Azkarate, A, Ramchandani, A, Fernández Montes, A, López, C, Longo, F, Sánchez Bayona, R, Limón, M L, Díaz-Serrano, A, Hurtado, A, Madero, R, Gómez, C, Gallego, J

“…Background: To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma…”
Get full text

Poisson balanced spiking networks by Rullán Buxó, Camille E, Pillow, Jonathan W

“…An important problem in computational neuroscience is to understand how networks of spiking neurons can carry out various computations underlying behavior…”
Get full text

Genetic relationships and diversity patterns within the invasive range of the Mediterranean Painted Frog by Pujol‐Buxó, E., Garcia‐Cisneros, A., Miaud, C., Llorente, G. A.

“…Range expansions are an intrinsic part of the biogeography of most species. Among them, some invasive species represent a paradigmatic case in which local…”
Get full text

Alien versus predators: effective induced defenses of an invasive frog in response to native predators by Pujol‐Buxó, E., García‐Guerrero, C., Llorente, G. A.

“…Inducible defenses enhance fitness of prey living in environments with unpredictable predation risk, but these plastic reactions depend on the detection of the…”
Get full text

Neutrophil-to-lymphocyte ratio as a biomarker for prognosis in localized colorectal carcinoma by Chic, N., Bruixola, G., Reig, O., Beveridge, R. Diaz, Buxo, E., Pineda, E., Prat, A., Aparicio, J., Maurel, J.

Get full text

First-line triplet or doublet chemotherapy for advanced gastric cancer: Analysis of 970 patients from a community practice registry by Diaz-Guardamino, I. Echavarria, Carmona-Bayonas, A., Fonseca, P. Jimenez, Martin, A.J. Muñoz, Lorenzo, M.L. Sanchez, Custodio, A., Garrido, M., Cano, J.M., Barreto, J.E. Lorenzo, Lacalle, A., Cardona, M. Ferrer, Manga, M., Visa, L., Buxo, E., Azkarate, A., Diaz, A., Ramchandani, A., Mugica, M., Sala, P., Alfonso, P. García

Get full text

A risk assessment model for predicting venous thromboembolic events in chemotherapy-treated germ-cell cancer by Luengo, M.I., Hervás, D., Sobrevilla, N., Muro, X. Garciadel, Padro, J. Guma I., Castellano, D., Aparicio, J., Muñoz, A. Sánchez, Buxo, E., Saenz, A., Aguilar, J.L., Valverde Morales, C., Fernández Aramburu, A., Maroto, P., Espinosa, M., Fonseca, P. Jimenez, Ros, S., Margeli, M., Sastre, J., Gonzalez-Billalabeitia, E.

Get full text

Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry by Carmona-Bayonas, A., Jiménez-Fonseca, P., Custodio, A., Sánchez Cánovas, M., Hernández, R., Pericay, C., Echavarria, I., Lacalle, A., Visa, L., Rodríguez Palomo, A., Mangas, M., Cano, J. M., Buxo, E., Álvarez-Manceñido, F., García, T., Lorenzo, J. E., Ferrer-Cardona, M., Viudez, A., Azkarate, A., Ramchandani, A., Arias, D., Longo, F., López, C., Sánchez Bayona, R., Limón, M. L., Díaz-Serrano, A., Fernández Montes, A., Sala, P., Cerdá, P., Rivera, F., Gallego, J.

“…Background Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including…”
Get full text

684PFIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH GASTROESOPHAGEAL ADENOCARCINOMA IN THE COMMUNITY SETTING: A MULTICENTER COHORT OF 418 PATIENTS by Garrido, M., Vicente Conesa, M.A., Carmona-Bayonas, A., Faez, L., Custodio, A., Lopez, C., Visa, L., Gallego Plazas, J., Fernandez Arrojo, S., Ramchandani, A., Múgica, M., Murias, C., Iranzo, V., Buxo, E., Hindi, N., Erpel, F., Pineda, E., Jofré, E., Giraldo, C., Jimenez Fonseca, P.

“…Abstract Aim: To display the first-line chemotherapy used in clinical practice and its efficacy and toxicity profile. Efficacy and toxicity grade 3-4…”
Get full text

634PPROGNOSTIC EVALUATION OF A MULTICENTER COHORT OF 484 PATIENTS WITH METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA by Vicente Conesa, M.A., Faez Garcia, L., Garrido, M., Custodio, A., López, C., Visa, L., Gallego Plazas, J., Fernandez Arrojo, S., Ramchandani, A., Murias, C., Iranzo, V., Múgica, M., Giraldo, C., Hindi, N., Erpel, F., Pineda, E., Buxo, E., Jofré, E., Jimenez Fonseca, P., Carmona-Bayonas, A.

“…Abstract Aim: To analyze the prognostic factors in patients with metastatic gastroesophageal adenocarcinoma treated with first-line chemotherapy. Methods: A…”
Get full text

First-Line Chemotherapy for Patients with Gastroesophageal Adenocarcinoma in the Community Setting: a Multicenter Cohort of 418 Patients by Garrido, M., Vicente Conesa, M.A., Carmona-Bayonas, A., Faez, L., Custodio, A., Lopez, C., Visa, L., Gallego Plazas, J., Fernandez Arrojo, S., Ramchandani, A., Múgica, M., Murias, C., Iranzo, V., Buxo, E., Hindi, N., Erpel, F., Pineda, E., Jofré, E., Giraldo, C., Jimenez Fonseca, P.

Get full text

Prognostic Evaluation of a Multicenter Cohort of 484 Patients with Metastatic Gastroesophageal Adenocarcinoma by Vicente Conesa, M.A., Faez Garcia, L., Garrido, M., Custodio, A., López, C., Visa, L., Gallego Plazas, J., Fernandez Arrojo, S., Ramchandani, A., Murias, C., Iranzo, V., Múgica, M., Giraldo, C., Hindi, N., Erpel, F., Pineda, E., Buxo, E., Jofré, E., Jimenez Fonseca, P., Carmona-Bayonas, A.

Get full text

1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma by Lordick, F., Chao, J., Buxò, E., van Laarhoven, H.W.M., Lima, C.M.R., Lorenzen, S., Dayyani, F., Heinemann, V., Greil, R., Stienen, S., Shitara, K.

Get full text

P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer by Lordick, F., Orra, E. Buxó, Cervantes, A., Dayyani, F., Rocha-Lima, C., Greil, R., Laarhoven, H. van, Lorenzen, S., Kischel, R., Shitara, K., Chao, J.

Get full text

1549P Molecular alterations (MA) with potential therapeutic implications in KRAS wild-type (WT) pancreatic cancer patients by Acosta Eyzaguirre, D.A., Verdaguer, H., Buxò, E., Garcia-Alvarez, A., Sardo, E., Hernando, J., Diez Garcia, M., Guardiola, M., Ros Montañá, F.J., Baraibar Argota, I., Saoudi, N., Marmolejo Castaneda, D.H., Aguilar, S., Sierra, A., Vivancos, A., Dienstmann, R., Macarulla Mercadé, T.

Get full text

MON-PO395: Nutritional Changes in Borderline Resectable Pancreatic Cancer Patients Along the Oncological Treatment by González-Tampán, R., Alonso, M., Arribas, L., Hurtós, L., López-Urdialez, R., Sánchez, C., Laquente, B., Buxó, E., Secanella, L., Leiva, D., Peiró, I.

Get full text

1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations by Garcia-Alvarez, A., Verdaguer, H., Guardiola, M., Acosta Eyzaguirre, D.A., Buxò, E., Sardo, E., Saoudi, N., Marmolejo Castaneda, D.H., Hernando, J., Diez Garcia, M., Baraibar Argota, I., Ros Montañá, F.J., Sierra, A., Molero, C., Miquel, J.M., Vivancos, A., Dienstmann, R., Macarulla Mercadé, T.

Get full text

1545P DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts) by Verdaguer, H., Guardiola, M., Mancuso, F.M., Acosta Eyzaguirre, D.A., Buxò, E., Hernando, J., Diez Garcia, M., Laquente, B., Baraibar Argota, I., Ros Montañá, F.J., Garcia-Alvarez, A., Matito, J., Martin, A., Sierra, A., Villacampa Javierre, G., Molero, C., Miquel, J.M., Vivancos, A., Dienstmann, R., Macarulla Mercadé, T.

Get full text

P-43 Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study by Longo, F., Fernandez, M. Jorge, Tur, R. Yaya, Montes, A. Fernández, Lago, N. Martínez, Vázquez, E. Brozos, Urtasun, J. Aparicio, Aldana, G. Quintero, Barbancho, E. Ceballos, Orra, E. Buxó, Muñoz, A. Lopez, Augusto, M. Pellón, Villaverde, R. Molina, Díaz-Paniagua, L., Serdà, P. Cerdà, López-Leiva, P., Martín-Carnicero, A., Castiñeiras, A. Cousillas, Bouzas, L. París, Paredes, B. García, Reinoso, C. Romero, Sedano, M. Ortega

Get full text